Jaypirca

Pirtobrutinib, the active ingredient in Jaypirca, is a Bruton tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for certain B‑cell malignancies, primarily in patients who have received prior therapies. GNH USA supplies Jaypirca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Jaypirca (pirtobrutinib) targets the Bruton tyrosine kinase pathway in B‑cell malignancies. It is used in the following clinical settings: - Mantle cell lymphoma: provides a treatment option for patients with relapsed or refractory disease after at least two prior lines of therapy. - Chronic lymphocytic leukemia/Small lymphocytic lymphoma: offers therapy for patients who have received prior treatment and require an alternative BTK‑targeted agent.

Adverse reactions to Jaypirca may vary in frequency and severity.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness not relieved by rest. - Nausea: occasional queasiness, often transient. - Rash: skin irritation or erythema. - Bruising: easy bruising due to platelet effects. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Hemorrhage: significant bleeding events, especially with anticoagulants. - Atrial fibrillation: new‑onset irregular heart rhythm. - Infections: opportunistic or severe bacterial, viral, or fungal infections. - Cytopenias: marked reductions in blood cell counts. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances. - Severe liver injury: elevated liver enzymes or hepatic failure.

Before initiating Jaypirca, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBCs to detect cytopenias. - Assess bleeding risk: evaluate concomitant anticoagulant or antiplatelet use. - Evaluate cardiac function: baseline ECG and periodic monitoring for arrhythmias. - Avoid strong CYP3A4 inhibitors: drugs like ketoconazole can increase exposure. - Use caution in hepatic impairment: dose adjustments may be needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Jaypirca may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase pirtobrutinib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for signs of hemorrhage. - Moderate CYP3A4 inhibitors (e.g., erythromycin): may require dose adjustment. - Moderate CYP3A4 inducers (e.g., phenytoin): observe for reduced therapeutic effect. - Live vaccines: consider timing to avoid compromised immune response.